// App-Quantinova.ai

P4-22-10 : Evaluation of the effects of palbociclib (PAL) + letrozole (LET) on QTc

Researchers

Presenter

  • A Ruiz

Principal Investigators

  • E Gauthier

  • C Durairaj

  • X Huang

  • J Hoffman

  • RS Finn

  • S Moulder

  • AA Joy

  • J Ettl

  • HS Rugo

  • D Wang

Medical Centers

  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA

  • University of California Los Angeles - David Geffen School of Medicine, Los Angeles, CA

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Frauenklinik und Poliklinik des Klinikums rechts der Isar, Technische Universitat Munchen, Munich, Germany

  • Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada

Locations

  • United States

  • Germany

  • Canada

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Palbociclib

  • Letrozole

Outcome

  • N/A

Study Design

  • non inferiority

  • double blind/blinded

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved